Home Page / News / Saadia Pharmaceuticals’ Team Publishes Rebutal on Vraylar® (AbbVie Pharmaceuticals) study on use for Bipolar I Disorder Maintenance

Saadia Pharmaceuticals’ Team Publishes Rebutal on Vraylar® (AbbVie Pharmaceuticals) study on use for Bipolar I Disorder Maintenance

Share an article:

Other News

September 10, 2024

In The News

Saadia Pharmaceuticals’ Team Gets Published in Nature

September 6, 2024

In The News

Saadia Pharmaceuticals’ Team Featured in Yale Psychiatry News

August 7, 2024

In The News

Saadia Pharmaceuticals’ Team Delivers NEI Podcast Discussing Vraylar®(Abbvie).

July 27, 2024

Posters & Publications

Saadia Pharmaceuticals’ Team Publishes Spravato® (Janssen) Review Article in Biomarkers in Neuropsychiatry

June 7, 2024

Posters & Publications

Saadia Pharmaceuticals’ Team Gives Presentation to 900K Prescribers on Vumedi

May 15, 2024

Posters & Publications